H1 2020 Lung Transplant Rejection - Pipeline Review - ResearchAndMarkets.com

The "Lung Transplant Rejection - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This latest report provides an overview of the Lung Transplant Rejection (Immunology) pipeline landscape.

Lung transplantation is the therapy used in various lung diseases. Lung transplant replaces an injured or diseased lung with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted lung as foreign and may work against it. Patients may hence develop complications and eventually reject the new organ.

Immunosuppressive drugs are administered simultaneously which prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Lung Transplant Rejection - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Lung Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Lung Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Lung Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 3 and 10 respectively.

Lung Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Lung Transplant Rejection (Immunology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Lung Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Report Coverage
• Lung Transplant Rejection - Overview
• Lung Transplant Rejection - Therapeutics Development
• Pipeline Overview
• Pipeline by Companies
• Products under Development by Companies
• Lung Transplant Rejection - Therapeutics Assessment
• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Lung Transplant Rejection - Companies Involved in Therapeutics Development
• Amgen Inc
• Apeptico Forschung und Entwicklung GmbH
• Astellas Pharma Inc
• Exscien Corp
• Kamada Ltd
• MimeTech Srl
• Proteo Inc
• Quark Pharmaceuticals Inc
• Radikal Therapeutics Inc
• Sangamo Therapeutics Inc
• TFF Pharmaceuticals Inc
• Theravance Biopharma Inc
• Lung Transplant Rejection - Drug Profiles
• Lung Transplant Rejection - Dormant Projects
• Lung Transplant Rejection - Product Development Milestones
• Featured News & Press Releases
• Oct 18, 2019: New insights into Alpha-1 Deficiency: A special scientific meeting organized by Kamada during the recent ERS congress
• Feb 06, 2019: Kamada announces additional interim results from phase 2 proof of concept clinical trial of intravenous Alpha-1 Antitrypsin treatment for prevention of Lung Transplant Rejection
• Jan 08, 2018: Kamada Announces Interim Results from Phase 2 Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection
• Jun 19, 2017: TxCell Appoints Lentigen Technology To Manufacture the Lentiviral Vector for Its First CAR-Treg Program in Transplant Rejection
• Apr 06, 2016: Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection
• Dec 09, 2015: Quark announces issue of U.S. patent for novel treatment of lung transplantation associated injury
• Oct 05, 2015: APEPTICO receives Orphan Drug Designation by European Medicines Agency
• Jun 22, 2015: Kamada Collaborates with Baxalta on Phase 1/2 Clinical Trial with Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection
• Mar 12, 2015: Elafin combined with cyclosporine promises to overcome limitations of cyclosporine for preventing irreversible damage to transplanted organs
• Mar 03, 2015: APEPTICO provides update on phase IIa study of AP301 product candidate
• Jul 08, 2013: APEPTICO receives research grant from Austrian Research Promotion Agency (FFG)
• Apr 17, 2013: APEPTICO initiates phase II clinical trial with AP301 in patients with primary graft dysfunction following lung transplantation
• Jan 31, 2013: APEPTICO announces publication of article in the journal Pulmonary Pharmacology and Therapeutics
• Dec 06, 2011: Proteo And Its Subsidiary Announce Major Advances In Elafin Development Program
• Sep 08, 2009: APEPTICO Presents Lead Product AP301 At Annual Congress Of European Respiratory Society In Vienna, Austria
• Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/3x7taj

View source version on businesswire.com: https://www.businesswire.com/news/home/20200817005228/en/